Literature DB >> 7250147

Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons.

J G Lloyd-Jones, P Robinson, R Henson, S R Biggs, T Taylor.   

Abstract

Buprenorphine is a newly-developed strong analgesic. A selected ion monitoring method has been developed to measure its plasma levels over the concentration range 20-3000ng ml-1. Six baboons each received intravenous and intramuscular doses of buprenorphine hydrochloride at a level of 5mg/kg in a cross-over study. The mean peak plasma concentrations (+/-standard deviation) were 2290 +/- 357ng ml-1 and 805 +/- 416ng ml-1 respectively and the corresponding times to the peak levels were 4.0 +/- 1.5 minutes and 30.3 +/- 24.6 minutes suggesting the rapid release of the drug from intramuscular sites. Comparison of areas under the plasma concentration versus time curves to 24 hours after dosing showed the mean bioavailability of buprenorphine from the intramuscular doses was 70% of that from the reference intravenous doses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7250147     DOI: 10.1007/BF03189469

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin.

Authors:  H B Kostenbauder; R P Rapp; J P McGovren; T S Foster; D G Perrier; H M Blacker; W C Hulon; A W Kinkel
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Mass fragmentography of morphine: relationship between brain levels and analgesic activity.

Authors:  P P Hipps; M R Eveland; E R Meyer; W R Sherman; T J Cicero
Journal:  J Pharmacol Exp Ther       Date:  1976-03       Impact factor: 4.030

3.  A double-blind comparison of morphine and buprenorphine in the prevention of pain after operation.

Authors:  B Kay
Journal:  Br J Anaesth       Date:  1978-06       Impact factor: 9.166

4.  Quantitative determination of morphine in serum by radioimmunoassay.

Authors:  S Spector
Journal:  J Pharmacol Exp Ther       Date:  1971-08       Impact factor: 4.030

5.  Concentration of propoxyphene in human plasma following oral, intramuscular, and intravenous administration.

Authors:  R L Wolen; C M Gruber; G F Kiplinger; N E Scholz
Journal:  Toxicol Appl Pharmacol       Date:  1971-07       Impact factor: 4.219

6.  Analgesic and dependence studies with oripavine partial agonists.

Authors:  A Cowan; J W Lewis; I R Macfarlane; B A Whittle
Journal:  Br J Pharmacol       Date:  1971-10       Impact factor: 8.739

7.  Quantitative gas chromatographic determination of picogram quantities of amino and alcoholic compounds by electron capture detection.

Authors:  T Walle; H Ehrsson
Journal:  Acta Pharm Suec       Date:  1971-03

8.  Quantitation of etorphine in urine by selective ion monitoring using tritiated etorphine as an internal standard.

Authors:  S P Jindal; P Vestergaard
Journal:  J Pharm Sci       Date:  1978-02       Impact factor: 3.534

9.  Clinical use of buprenorphine in chronic administration.

Authors:  H Adriaensen; J Van De Walle
Journal:  Acta Anaesthesiol Belg       Date:  1976

10.  Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat.

Authors:  B E Dahlström; L K Paalzow
Journal:  J Pharmacokinet Biopharm       Date:  1978-12
  10 in total
  5 in total

1.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

2.  The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.

Authors:  Jermaine D Jones; Gabriela Madera; Sandra D Comer
Journal:  Pharmacol Biochem Behav       Date:  2014-05-02       Impact factor: 3.533

3.  Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency.

Authors:  Germán Gustavo Gornalusse; Lucia N Vojtech; Claire N Levy; Sean M Hughes; Yeseul Kim; Rogelio Valdez; Urvashi Pandey; Christina Ochsenbauer; Rena Astronomo; Julie McElrath; Florian Hladik
Journal:  Viruses       Date:  2021-07-27       Impact factor: 5.818

4.  Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis).

Authors:  Elizabeth A Nunamaker; Lisa C Halliday; David E Moody; Wenfang B Fang; Matthew Lindeblad; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-01       Impact factor: 1.232

5.  Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta).

Authors:  K R Kelly; B H Pypendop; K L Christe
Journal:  J Vet Pharmacol Ther       Date:  2014-03-25       Impact factor: 1.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.